Medeor Therapeutics
2012
FOUNDED
PRIVATE
STATUS
Series B
LATEST DEAL TYPE
$57M
LATEST DEAL AMOUNT
5
INVESTORS
Description
Developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's cellular immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 1875 South Grant Street
- Suite 130
- San Mateo, CA 94402
- United States
+1 (650) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Medeor Therapeutics’s full profile, request a free trial.
Medeor Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series B) | 27-Nov-2017 | $57M | 000.00 | 00000 | Completed | Clinical Trials - General |
| 3. Early Stage VC (Series A) | 16-Oct-2015 | 000 | 000.00 | 0000 | Completed | Clinical Trials - General |
| 2. Early Stage VC | 02-Oct-2013 | $1.55M | $2.55M | 000.00 | Completed | Clinical Trials - General |
| 1. Seed Round | 11-Jan-2013 | $1M | $1M | 000 | Completed | Clinical Trials - General |
Medeor Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
| Series A | 0,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
| Seed 1 | 1,291,667 | $0.000100 | 8% | $1.2 | $1.2 | 1x | $1.2 | 4.67% |
| Seed | 1,000,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 3.61% |
Medeor Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| 6 Dimensions Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| RA Capital Management | Asset Manager | Minority | 000 0000 | 000000 0 | ||
| Sofinnova Investments | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Vivo Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| WuXi Healthcare Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |
Medeor Therapeutics Executive Team (10)
2 Former Executives
You’re viewing 5 of 10 executives. Get the full list »Medeor Therapeutics Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Anand Mehra MD | Sofinnova Investments | Board Member | 000 0000 | |
| Frank Kung Ph.D | Vivo Capital | Board Member | 000 0000 | |
| Peter Kolchinsky Ph.D | RA Capital Management | Board Member | 000 0000 | |
| Steven Deitcher MD | Medeor Therapeutics | Co-Founder, Chief Executive Officer, President and Board Member | 000 0000 | |
| Wei Li Ph.D | WuXi Healthcare Ventures | Board Member | 000 0000 |
2 Former Board Members
You’re viewing 5 of 7 board members. Get the full list »